Organoid-based Regenerative medicine (ATORM)

ORGANOIDSCIENCES, Ltd. is a South Korea’s first biotech to develop first-in-class regenerative medicine for incurable diseases.

As we all know, organoids are a promising strategy in the field of regenerative medicine and transplantation with high levels of regenerative capacities and low risk of tumorigenicity. We have developed the proprietary technologies for manufacturing clinical-grade organoids for patients.

We would like to establish partnerships with companies which might potentiate to develop our pipeline abroad. We have various pipelines, including the ATORM-CD (Adult tissue derived organoid-based regnerative medicine) pipeline to treat fistulating or ulcerating Crohn’s disease.

Please see the attachment for further information.
We would also like to present more details of our innovative platforms for the drug development and discuss any possible collaborations.